Conjugation

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Retrieved on: 
Monday, April 8, 2024
Gene silencing, Irinotecan, Colorectal cancer, Immunotherapy, Triple-negative breast cancer, Mouse, Observation, Endocytosis, Cancer, Christian democracy, SN-38, Senior, Camptothecin, Conjugation, AACR, TSX, Treatment, Neoplasm, CRC, Poster, HT-29, TNBC, PDC, Vaccine

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.
  • The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads.
  • “In addition to our lead peptide-drug conjugate, sudocetaxel zendusortide, these latest data highlight the promising tolerability and anti-tumor effects of our investigational camptothecin-peptide conjugates, further demonstrating the versatility and flexibility of the platform.
  • In the poster presented at AACR, the investigators noted that SORT1 gene silencing inhibits camptothecin-conjugate uptake in human HT-29 colorectal adenocarcinoma cells.

Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit

Retrieved on: 
Friday, April 5, 2024
Spacecraft, Antibody, ADC, Cleveland Clinic, Conjugation, JPMorgan Chase, Antibody-drug conjugate

Unlike current ADCs, Medicovestor's groundbreaking first-in-class ADC platforms prioritize the "A" (antibody) over the "DC" (drug conjugate), harnessing the intrinsic antitumor activities of the backbone antibody.

Key Points: 
  • Unlike current ADCs, Medicovestor's groundbreaking first-in-class ADC platforms prioritize the "A" (antibody) over the "DC" (drug conjugate), harnessing the intrinsic antitumor activities of the backbone antibody.
  • "We are thrilled to be selected as a finalist for this prestigious summit," said Dr. Seah Lim , Founder and CEO of Medicovestor.
  • The Life Sciences Innovation Summit, hosted by JP Morgan Asset Management, serves as a prestigious platform for leading innovators, investors, and industry experts to explore cutting-edge advancements in healthcare and life sciences.
  • During the summit, Medicovestor aims to share insights into its ADC platform development, preclinical progress, and future prospects.

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Retrieved on: 
Wednesday, March 27, 2024
Brolucizumab, Sale, Acquisition, Conjugation, Cancer, Antibody, Therapy, ADC, Antibody-drug conjugate

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rights to royalties from the commercialization of Beovu® (brolucizumab-dbll) and another asset to Novartis for a one-time cash payment of $8 million.

Key Points: 
  • Under the agreement with Novartis, Pyxis Oncology will receive an $8 million payment from Novartis.
  • Royalties previously received by Apexigen and Pyxis Oncology will be free from any reclaim rights.
  • Pyxis Oncology will record the $8 million payment in Q1 2024.
  • Pyxis Oncology retains rights to three other antibodies in development by Apexigen's licensees, which were also discovered leveraging the APXiMAB platform.

Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer

Retrieved on: 
Tuesday, April 9, 2024
UBS, Biotechnology, CFO, Business, Patient, CBC, SAN, Cancer, Spacecraft, Pleasure, Wellesley College, Conjugation, Therapy, ADC, Antibody-drug conjugate, Management

SAN DIEGO and SHANGHAI, April 8, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).

Key Points: 
  • SAN DIEGO and SHANGHAI, April 8, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).
  • Ms. Jiang joins Adcentrx from CBC Group where she was Senior Managing Director and Management Committee Member.
  • "We are delighted to welcome Meng to Adcentrx's executive leadership team," said Hui Li, Ph.D., Founder and CEO of Adcentrx.
  • "We are glad to see Meng's continued contributions to Adcentrx as Chief Financial Officer," said Fu Wei, Chief Executive Officer at CBC Group.

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform

Retrieved on: 
Monday, March 18, 2024
Patient, Bystander effect, OBI, Cancer, Spacecraft, CDX, AACR, PDX, PARP, Conjugation, Safety, ADC, Pharmaceutical industry

TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC).

Key Points: 
  • TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC).
  • When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, superior PK/PD properties, and a favorable safety profile across various preclinical animal models.
  • Additionally, preclinical data will be presented on the novel site-specific proprietary GlycOBI™ ADC platform, demonstrating improved in vivo efficacy and stability in animal model studies.
  • These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 5 to 10, 2024 in San Diego, California (USA).

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cell proliferation, Development, Growth, Apoptosis, ELCC, Carcinoma, Partnership, Patient, Neoplasm, Bystander effect, Tumor microenvironment, IND, CDX, Conjugation, PDX, DLL3, HKEX, ADC, SCLC

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company’s global next-generation antibody-drug conjugate (ADC) program.

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company’s global next-generation antibody-drug conjugate (ADC) program.
  • ZL-1310 is a novel and promising ADC within the Zai Lab global oncology R&D pipeline, targeting the Delta-like ligand 3 (DLL3), a validated therapeutic target in the treatment of small cell lung cancer (SCLC).
  • Zai Lab entered a partnership and exclusive worldwide license agreement with MediLink in April 2023.
  • Subsequently, in January 2024, Zai Lab initiated a global Phase 1 study of ZL-1310 in patients with relapsed and refractory SCLC who have progressed after platinum-based treatment.

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR

Retrieved on: 
Thursday, April 4, 2024
Brain, Bone marrow, Drug discovery, Patient, CNS, Research, IRBM, Cancer, Doctor of Philosophy, MD, AACR, Conjugation, ADC, Antibody-drug conjugate, Compound, Pharmaceutical industry

The data will reveal insights into the novel compounds developed to address critical unmet needs in cancer treatment.

Key Points: 
  • The data will reveal insights into the novel compounds developed to address critical unmet needs in cancer treatment.
  • Potential first-in-class Antibody-Drug Conjugate (ADC) targeting CRLF2/TLSPR in "Ph-like" B-ALL (AM E3-SG3249) demonstrated significant preclinical efficacy, representing a pioneering approach to treating hematologic cancer characterized by poor prognosis and high relapse rates, often affecting adolescents.
  • Potential best-in-class brain permeable SHP2 allosteric inhibitor (I-1000233) exhibited promising results in preclinical studies, offering a new method of treating patients with RAS-driven malignancies, including challenging brain tumors and metastases.
  • These developments reflect our deep scientific expertise and innovative spirit, underscoring IRBM's role as a frontrunner in the integrated drug discovery industry."

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR

Retrieved on: 
Thursday, April 4, 2024
Brain, Bone marrow, Drug discovery, Patient, CNS, Research, IRBM, Cancer, Doctor of Philosophy, MD, AACR, Conjugation, ADC, Antibody-drug conjugate, Compound, Pharmaceutical industry

The data will reveal insights into the novel compounds developed to address critical unmet needs in cancer treatment.

Key Points: 
  • The data will reveal insights into the novel compounds developed to address critical unmet needs in cancer treatment.
  • Potential first-in-class Antibody-Drug Conjugate (ADC) targeting CRLF2/TLSPR in "Ph-like" B-ALL (AM E3-SG3249) demonstrated significant preclinical efficacy, representing a pioneering approach to treating hematologic cancer characterized by poor prognosis and high relapse rates, often affecting adolescents.
  • Potential best-in-class brain permeable SHP2 allosteric inhibitor (I-1000233) exhibited promising results in preclinical studies, offering a new method of treating patients with RAS-driven malignancies, including challenging brain tumors and metastases.
  • These developments reflect our deep scientific expertise and innovative spirit, underscoring IRBM's role as a frontrunner in the integrated drug discovery industry."

Adcentrx Therapeutics to Present Preclinical Data for Nectin-4 ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Monday, April 1, 2024
Biotechnology, DAR, SAN, Neoplasm, Bystander effect, Immunoglobulin G, Cancer, Spacecraft, AACR, Monomethyl auristatin E, Clinical trial, Conjugation, Therapy, ADC, Antibody-drug conjugate, Pharmaceutical industry

Preclinical data support clear differentiation of Adcentrx's platform and lead program, ADRX-0706, currently being evaluated in a Phase 1a/b clinical trial

Key Points: 
  • Preclinical data support clear differentiation of Adcentrx's platform and lead program, ADRX-0706, currently being evaluated in a Phase 1a/b clinical trial
    SAN DIEGO, April 1, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced that preclinical data for ADRX-0706 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 , taking place April 5-10, 2024, in San Diego, CA.
  • The three presentations will include preclinical data for Adcentrx's lead ADC program, ADRX-0706.
  • The preclinical data presentations show improved therapeutic window of ADRX-0706, enhanced bystander effect and improved payload delivery to Nectin-4 expressing tumors while minimizing exposure to normal tissues.
  • Details of the three AACR poster presentations are below:
    Presentation Title: Advancing a novel tubulin-inhibitor ADC technology: The Adcentrx auristatin platform offers enhanced efficacy and safety profiles compared to vedotin technology

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, February 28, 2024
G1 Therapeutics, Breast cancer, Carboplatin, Research, PIN, SCLC, Telephone, Update, J. P. Morgan, DMC, Food, Growth, SACT, G1, Trilaciclib, Hospital, ADC, OS, Conjugation, GAAP, Event, Therapy, Webcast, Patent, Patient, Acceleration, Clinical trial, Survival, Oncology, ITT, Pharmaceutical industry

G1 recognized total revenues of $14.9 million and $82.5 million for the fourth quarter and full year of 2023, respectively.

Key Points: 
  • G1 recognized total revenues of $14.9 million and $82.5 million for the fourth quarter and full year of 2023, respectively.
  • Operating expenses for the fourth quarter of 2023 were $23.8 million, compared to $41.1 million for the fourth quarter of 2022.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $7.4 million, compared to $16.6 million for the fourth quarter of 2022.
  • The net loss for the fourth quarter of 2023 was $10.9 million, compared to $33.6 million for the fourth quarter of 2022.